Coherus Confident On Avastin This Year With Humira Goal Achieved

Filing Of Adalimumab Was Slated For Q4 2020

 
• By Dean Rudge

Having delivered on a goal to file its Humira biosimilar with the FDA by the end of last year, Coherus BioSciences is now focused on getting its in-licensed bevacizumab product filing over the line, as it scans the market for further growth opportunities.

Light bulb
Coherus is aiming to file its partnered bevacizumab in the back half of this year. • Source: Shutterstock

Coherus BioSciences is on course to file a biologics license application in the US for partner Innovent Biologics’ Avastin (bevacizumab) biosimilar in the second half of 2021, management has revealed, after confirming that Coherus’ wholly-owned Humira (adalimumab) biosimilar application has now been filed with the US Food and Drug Administration.

“We project the BLA filing for the second half of 2021

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products